Bain Capital Life Sciences

Funding rounds backed by Bain Capital Life Sciences.

Export CSV
Funding disclosed in full
$566M
Median round
$92.5M
Rounds in calculation
4
4 rounds
LatestLargest
Funding rounds with company descriptions, amounts, stages and announcement dates
CompanyRoundMarketInvestorsAnnouncedDetails
Abcuro

Develops immunotherapies that selectively deplete cytotoxic T cells to treat autoimmune diseases

$66MSeries DBiotechUnited States
17 participantsabrdnBain Capital Life SciencesEurofarma VenturesForesite CapitalKaitai CapitalMass General Brigham VenturesNancy ChangNew Enterprise Associates (NEA)New Leaf Venture PartnersPontifaxRA Capital ManagementRedmile GroupRock Springs CapitalSamsara BioCapitalSanofi VenturesShang BaySoleus Capital
AdvanCell

Develops lead-212 targeted alpha therapies to treat cancer

$315MSeries DBiotechAustralia
19 participantsAbingworthAlly Bridge GroupAlpha WaveBain Capital Life SciencesBrandon CapitalCatalio Capital ManagementEli Lilly and CompanyEventide Asset ManagementFidelity Management & Research CompanyMorningsidePiper HeartlandProto AxiomSanofi VenturesSV Health InvestorsSymBiosisTenmileTime BioVenturesT. Rowe Price AssociatesVelosity Capital
CereVasc

Develops minimally invasive eShunt System to treat communicating hydrocephalus and other neurological diseases

$85MSeries CHealthtechUnited States
5 participantsBain Capital Life SciencesJohnson & Johnson Innovation – JJDCMedtronicPerceptive Xontogeny Venture FundsPiper Sandler Merchant Banking
Imperative Care

Develops treatments for patients suffering from thromboembolic disease

$100MGrowthHealthtechUnited States
7 participantsAlly Bridge GroupBain Capital Life SciencesBrown AdvisoryCatalio Capital ManagementElevage Medical TechnologiesLongaeva PartnersPerceptive Advisors